Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Musante, Luca ^a   Tataruch, Dorota ^a   Gu, Dongfeng ^a   Liu, Xinyu ^a   Forsblom, Carol ^b,c,d   Groop, Per Henrik ^b   Holthofer, Harry ^a,e  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN H; CATHEPSIN L; CYSTATIN B; ELAFIN; MYELOBLASTIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEINASE; PROTEINASE INHIBITOR; PYROXYLIN; BIOLOGICAL MARKER; PEPTIDE HYDROLASE;

ADULT; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIALYSIS; FEMALE; HUMAN; IMMUNODETECTION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; URINALYSIS; URINARY EXTRACELLULAR VESICLE; URINARY TRACT; ZYMOGRAPHY; BIOPSY; CHEMISTRY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; EXOSOME; FILTRATION; GLOMERULUS FILTRATION RATE; METABOLISM; MULTICENTER STUDY; NORMAL HUMAN; RISK FACTOR; URINE; YOUNG ADULT;

ADULT; ALBUMINURIA; BIOMARKERS; BIOPSY; CYSTATIN B; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; EXTRACELLULAR VESICLES; FEMALE; FILTRATION; GLOMERULAR FILTRATION RATE; HEALTHY VOLUNTEERS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MYELOBLASTIN; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; RISK FACTORS; YOUNG ADULT;

EID: 84926434307     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/289734     Document Type: Article

References (78)

1. N. M. Maruthur, "The growing prevalence of type 2 diabetes: increased incidence or improved survival?" Current Diabetes Reports, Vol. 13, no. 6, pp. 786-794, 2013.
2. S. van Dieren, J. W. J. Beulens, Y. T. van der Schouw, D. E. Grobbee, and B. Neal, "The global burden of diabetes and its complications: an emerging pandemic," European Journal of Cardiovascular Prevention and Rehabilitation, Vol. 17, no. 1, pp. s3-s8, 2010.
3. A. J. Collins, R. N. Foley, B. Chavers et al., "US Renal Data System 2013 Annual Data Report," American Journal of Kidney Diseases, Vol. 63, no. S1, p. A7, 2014.
4. R. C. Atkins and P. Zimmet, "World Kidney Day 2010: diabetic kidney disease - act now or pay later," The American Journal of Kidney Diseases, Vol. 55, no. 2, pp. 205-208, 2010.
5. S. Selvarajah, C. S. P. M. Uiterwaal, J. Haniff et al., "Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus," European Journal of Clinical Investigation, Vol. 43, no. 2, pp. 198-207, 2013.
6. G. Targher, G. Zoppini, M. Chonchol et al., "Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals," Nutrition, Metabolism and Cardiovascular Diseases, Vol. 21, no. 4, pp. 294-301, 2011.
7. P.-H. Groop, M. C. Thomas, J. L. Moran et al., "The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes," Diabetes, Vol. 58, no. 7, pp. 1651-1658, 2009.
8. Y. S. Kanwar, L. Sun, P. Xie, F.-Y. Liu, and S. Chen, "A glimpse of various pathogenetic mechanisms of diabetic nephropathy," Annual Review of Pathology: Mechanisms of Disease, Vol. 6, no. 1, pp. 395-423, 2011.
9. M. K. Arora and U. K. Singh, "Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update," Vascular Pharmacology, Vol. 58, no. 4, pp. 259-271, 2013.
10. D. Fineberg, K. A. M. Jandeleit-Dahm, and M. E. Cooper, "Diabetic nephropathy: diagnosis and treatment," Nature Reviews Endocrinology, Vol. 9, no. 12, pp. 713-723, 2013.
11. A. S. Krolewski and J. V. Bonventre, "High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline," Seminars in Nephrology, Vol. 32, no. 5, pp. 407-414, 2012.
12. G. Jerums, S. Panagiotopoulos, E. Premaratne, and R. J. MacIsaac, "Integrating albuminuria and GFR in the assessment of diabetic nephropathy," Nature Reviews Nephrology, Vol. 5, no. 7, pp. 397-406, 2009.
13. American Diabetes Association, "Standards of medical care in diabetes," Diabetes Care, Vol. 32, supplement 1, pp. S13-S61, 2009.
14. KDOQI, "Guideline 1: screening and diagnosis of diabetic kidney disease," The American Journal of Kidney Diseases, Vol. 49, supplement 2, pp. S42-S61, 2009.
15. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, and R. R. Holman, "Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)," Kidney International, Vol. 63, no. 1, pp. 225-232, 2003.
16. G. Remuzzi, A. Benigni, and A. Remuzzi, "Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes," Journal of Clinical Investigation, Vol. 116, no. 2, pp. 288-296, 2006.
17. B. A. Perkins, L. H. Ficociello, B. Roshan, J. H. Warram, and A. S. Krolewski, "In patients with type 1 diabetes and newonset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria," Kidney International, Vol. 77, no. 1, pp. 57-64, 2010.
18. T. Pisitkun, R.-F. Shen, and M. A. Knepper, "Identification and proteomic profiling of exosomes in human urine," Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, no. 36, pp. 13368-13373, 2004.
19. P. A. Gonzales, T. Pisitkun, J. D. Hoffert et al., "Large-scale proteomics and phosphoproteomics of urinary exosomes," Journal of the American Society of Nephrology, Vol. 20, no. 2, pp. 363-379, 2009.
20. K. C. Miranda, D. T. Bond, M. McKee et al., "Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease," Kidney International, Vol. 78, no. 2, pp. 191-199, 2010.
21. G. Raposo and W. Stoorvogel, "Extracellular vesicles: exosomes, microvesicles, and friends," The Journal of Cell Biology, Vol. 200, no. 4, pp. 373-383, 2013.
22. J. C. Akers, D. Gonda, R. Kim, B. S. Carter, and C. C. Chen, "Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies," Journal of Neuro-Oncology, Vol. 113, no. 1, pp. 1-11, 2013.
23. A. L. Sun, J. T. Deng, G. J. Guan et al., "Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease," Diabetes and Vascular Disease Research, Vol. 9, no. 4, pp. 301-308, 2012.
24. I. Zubiri, M. Posada-Ayala, A. Sanz-Maroto et al., "Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis," Journal of Proteomics, Vol. 96, pp. 92-102, 2014.
25. F. Barutta, M. Tricarico, A. Corbelli et al., "Urinary exosomal MicroRNAs in incipient diabetic nephropathy," PLoS ONE, Vol. 8, no. 11, Article ID e73798, 2013.
26. L. Musante, D. Tataruch, D. Gu et al., "A simplified method to recover urinary vesicles for clinical applications," Scientific Reports, Vol. 4, article 7532, 2014.
27. M. M. Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding," Analytical Biochemistry, Vol. 72, no. 1-2, pp. 248-254, 1976.
28. U. K. Laemmli, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," Nature, Vol. 227, no. 15, pp. 680-685, 1970.
29. T. Rabilloud, "Detergents and chaotropes for protein solubilization before two-dimensional electrophoresis," Methods in Molecular Biology, Vol. 528, no. 4, pp. 259-267, 2009.
30. G. Candiano, M. Bruschi, L. Musante et al., "Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis," Electrophoresis, Vol. 25, no. 9, pp. 1327-1333, 2004.
31. H. Towbin, T. Staehelin, and J. Gordon, "Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications," Proceedings of the National Academy of Sciences of the United States of America, Vol. 76, no. 9, pp. 4350-4354, 1979.
32. D. E. Kleiner and W. G. Stetler-Stevenson, "Quantitative zymography: detection of picogram quantities of gelatinases," Analytical Biochemistry, Vol. 218, no. 2, pp. 325-329, 1994.
33. A. Fullaondo, S. García-Sánchez, A. Sanz-Parra, E. Recio, S. Y. Lee, and D. Gubb, "Spn1 regulates the GNBP3-dependent toll signaling pathway in Drosophila melanogaster," Molecular and Cellular Biology, Vol. 31, no. 14, pp. 2960-2972, 2011.
34. O. Wiesner, R. D. Litwiller, A. M. Hummel et al., "Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments," FEBS Letters, Vol. 579, no. 24, pp. 5305-5312, 2005.
35. P. J. Hogg, D. A. Owensby, and C. N. Chesterman, "Thrombospondin 1 is a tight-binding competitive inhibitor of neutrophil cathepsin G. Determination of the kinetic mechanism of inhibition and localization of cathepsin G binding to the thrombospondin 1 type 3 repeats," The Journal of Biological Chemistry, Vol. 268, no. 29, pp. 21811-21818, 1993.
36. B. E. Cham and B. R. Knowles, "A solvent system for delipidation of plasma or serum without protein precipitation," The Journal of Lipid Research, Vol. 17, no. 2, pp. 176-181, 1976.
37. A. Varshavsky, "The ubiquitin system, an immense realm," Annual Review of Biochemistry, Vol. 81, no. 9, pp. 167-176, 2012.
38. J. Klein, S. Jupp, P. Moulos et al., "The KUPKB: a novel Web application to access multiomics data on kidney disease," The FASEB Journal, Vol. 26, no. 5, pp. 2145-2153, 2012.
39. K. M. Thrailkill, R. Clay Bunn, and J. L. Fowlkes, "Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy," Endocrine, Vol. 35, no. 1, pp. 1-10, 2009.
40. H. J. Baelde, M. Eikmans, P. P. Doran, D. W. P. Lappin, E. De Heer, and J. A. Bruijn, "Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy," The American Journal of Kidney Diseases, Vol. 43, no. 4, pp. 636-650, 2004.
41. R. J. MacIsaac, E. I. Ekinci, and G. Jerums, "'Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'," Kidney International, Vol. 86, no. 1, pp. 50-57, 2014.
42. R. J. Macisaac, E. I. Ekinci, and G. Jerums, "Markers of and risk factors for the development and progression of diabetic kidney disease," American Journal of Kidney Diseases, Vol. 63, no. 2, pp. S39-S62, 2014.
43. T. Wollert and J. H. Hurley, "Molecular mechanism of multivesicular body biogenesis by ESCRT complexes," Nature, Vol. 464, no. 7290, pp. 864-869, 2010.
44. E. Cocucci, G. Racchetti, and J. Meldolesi, "Shedding microvesicles: artefacts no more," Trends in Cell Biology, Vol. 19, no. 2, pp. 43-51, 2009.
45. T. J. Greenwalt, "The how and why of exocytic vesicles," Transfusion, Vol. 46, no. 1, pp. 143-152, 2006.
46. H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells," Nature Cell Biology, Vol. 9, no. 6, pp. 654-659, 2007.
47. J. W. Dear, J. M. Street, and M. A. Bailey, "Urinary exosomes: a reservoir for biomarker discovery and potential mediators of intrarenal signalling," Proteomics, Vol. 13, no. 10-11, pp. 1572-1580, 2013.
48. T. Gohda, W. H. Walker, P. Wolkow et al., "Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes," The American Journal of Physiology - Renal Physiology, Vol. 303, no. 1, pp. F157-F162, 2012.
49. O. Bakoush, J. Tencer, J. Tapia, B. Rippe, and O. Torffvit, "Higher urinary IgM excretion in type 2 diabetic nephropathy compared to type 1 diabetic nephropathy," Kidney International, Vol. 61, no. 1, pp. 203-208, 2002.
50. P. van Damme, M. Lasa, B. Polevoda et al., "N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB," Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, no. 31, pp. 12449-12454, 2012.
51. I. Amit, L. Yakir, M. Katz et al., "Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding," Genes and Development, Vol. 18, no. 14, pp. 1737-1752, 2004.
52. J. H. Hurley, E. Boura, L.-A. Carlson, and B. Róycki, "Membrane budding," Cell, Vol. 143, no. 6, pp. 875-887, 2010.
53. V. I. Korolchuk, F. M. Menzies, and D. C. Rubinsztein, "Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems," FEBS Letters, Vol. 584, no. 7, pp. 1393-1398, 2010.
54. U. Panchapakesan, A. Mather, and C. Pollock, "Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease," Clinical Science, Vol. 124, no. 1, pp. 17-26, 2013.
55. C. W. Mende, "Application of direct renin inhibition to chronic kidney disease," Cardiovascular Drugs and Therapy, Vol. 24, no. 2, pp. 139-149, 2010.
56. A. Wyczalkowska-Tomasik, I. Bartlomiejczyk, B. Gornicka, and L. Paczek, "Strong association between fibronectin accumulation and lowered cathepsin B activity in glomeruli of diabetic rats," Journal of Physiology and Pharmacology, Vol. 63, no. 5, pp. 525-530, 2012.
57. R. H. Song, A. K. Singh, and D. J. Leehey, "Decreased glomerular proteinase activity in the streptozotocin diabetic rat," American Journal of Nephrology, Vol. 19, no. 3, pp. 441-446, 1999.
58. V. Turk and W. Bode, "The cystatins: protein inhibitors of cysteine proteinases," FEBS Letters, Vol. 285, no. 2, pp. 213-219, 1991.
59. N. Malla, S. Sjøli, J.-O. Winberg, E. Hadler-Olsen, and L. Uhlin-Hansen, "Biological and pathobiological functions of gelatinase dimers and complexes," Connective Tissue Research, Vol. 49, no. 3-4, pp. 180-184, 2008.
60. A. Lacquaniti, V. Donato, B. Pintaudi et al., "'Normoalbuminuric' diabetic nephropathy: tubular damage and NGAL," Acta Diabetologica, Vol. 50, no. 6, pp. 935-942, 2013.
61. L. Pala, E. Mannucci, A. Pezzatini et al., "Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells," Biochemical and Biophysical Research Communications, Vol. 310, no. 1, pp. 28-31, 2003.
62. D. Stiller, H. Bahn, and C. August, "Demonstration of glomerular DPP IV activity in kidney diseases," Acta Histochemica, Vol. 91, no. 1, pp. 105-109, 1991.
63. M. Elleder and J. Stejskal, "Induction of dipeptidylpeptidase IV activity in human renal glomeruli - a histochemical study," Acta Histochemica, Vol. 77, no. 1, pp. 75-78, 1985.
64. B. E. P. B. Ballieux, P. S. Hiemstra, N. Klar-Mohamad et al., "Detachment and cytolysis of human endothelial cells by proteinase 3," European Journal of Immunology, Vol. 24, no. 12, pp. 3211-3215, 1994.
65. D. Novick, M. Rubinstein, T. Azam, A. Rabinkov, C. A. Dinarello, and S.-H. Kim, "Proteinase 3 is an IL-32 binding protein," Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, no. 9, pp. 3316-3321, 2006.
66. M. Navarrete, J. Ho, O. Krokhin et al., "Proteomic characterization of serine hydrolase activity and composition in normal urine," Clinical Proteomics, Vol. 10, article 17, 2013.
67. S. J. Kuravi, A. Bevins, S. C. Satchell et al., "Neutrophil serine proteases mediate inflammatory cell recruitment by glomerular endothelium and progression towards dysfunction," Nephrology Dialysis Transplantation, Vol. 27, no. 12, pp. 4331-4338, 2012.
68. S. J. Kuravi, H. M. McGettrick, S. C. Satchell et al., "Podocytes regulate neutrophil recruitment by glomerular endothelial cells via IL-6-mediated crosstalk," The Journal of Immunology, Vol. 193, no. 1, pp. 234-243, 2014.
69. J. J. Yang, R. Kettritz, R. J. Falk, J. C. Jennette, and M. L. Gaido, "Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase," The American Journal of Pathology, Vol. 149, no. 5, pp. 1617-1626, 1996.
70. J. J. Yang, G. A. Preston, W. F. Pendergraft et al., "Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants," The American Journal of Pathology, Vol. 158, no. 2, pp. 581-592, 2001.
71. S. Bae, J. Choi, J. Hong et al., "Neutrophil proteinase 3 induces diabetes in a mouse model of glucose tolerance," Endocrine Research, Vol. 37, no. 1, pp. 35-45, 2012.
72. M. S. Roy, M. N. Janal, J. Crosby, and R. Donnelly, "Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes," Kidney International, Vol. 87, pp. 427-433, 2014.
73. C. Ouyang, J. You, and Z. Xie, "The interplaybetween autophagy and apoptosis in the diabetic heart," Journal of Molecular and Cellular Cardiology, Vol. 71, pp. 71-80, 2014.
74. D. Kim, S. Lim, M. Park et al., "Ubiquitination-dependent CARM1 degradation facilitates Notch1-mediated podocyte apoptosis in diabetic nephropathy," Cellular Signalling, Vol. 26, no. 9, pp. 1774-1782, 2014.
75. D. A. Johnson, A. J. Barrett, and R. W. Mason, "Cathepsin L inactivates α1-proteinase inhibitor by cleavage in the reactive site region," Journal of Biological Chemistry, Vol. 261, no. 31, pp. 14748-14751, 1986.
76. K. Kessenbrock, V. Plaks, and Z. Werb, "Matrix metalloproteinases: regulators of the tumor microenvironment," Cell, Vol. 141, no. 1, pp. 52-67, 2010.
77. S. Ray, P. Lukyanov, and J. Ochieng, "Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities," Biochimica et Biophysica Acta - Proteins and Proteomics, Vol. 1652, no. 2, pp. 91-102, 2003.
78. C. H. Pan, C. H. Wen, and C. S. Lin, "Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes," Experimental Physiology, Vol. 93, no. 5, pp. 599-612, 2008.